Human papillomavirus infection and seroprevalence among female university students in Mexico

References

• Bravo IG, Felez-Sanchez M. Papillomaviruses: viral evolution, cancer and evolutionary medicine. Evol Med Public Health. 2015;2015:32–12. doi:10.1093/emph/eov003.
   PubMedGoogle Scholar
• Aguilar-Lemarroy A, Vallejo-Ruiz V, Cortes-Gutierrez EI, Salgado-Bernabe ME, Ramos-Gonzalez NP, Ortega-Cervantes L, Arias‐Flores R, Medina‐Díaz IM, Hernández‐Garza F, Santos‐López G, Piña‐Sánchez P. Human papillomavirus infections in Mexican women with normal cytology, precancerous lesions, and cervical cancer: type-specific prevalence and HPV coinfections. J Med Virol. 2015;87:871–84. doi:10.1002/jmv.24099.
   PubMed Web of Science ®Google Scholar
• Boda D, Docea AO, Calina D, Ilie MA, Caruntu C, Zurac S, Neagu M, Constantin C, Branisteanu DE, Voiculescu V, et al. Human papilloma virus: apprehending the link with carcinogenesis and unveiling new research avenues (Review). Int J Oncol. 2018;52:637–55. doi:10.3892/ijo.2018.4256.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF, Peto J, Meijer CJLM, Muñoz N, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.
   PubMed Web of Science ®Google Scholar
• Handler NS, Handler MZ, Majewski S, Schwartz RA. Human papillomavirus vaccine trials and tribulations: vaccine efficacy. J Am Acad Dermatol. 2015;73:759–67. quiz 67-8. doi:10.1016/j.jaad.2015.05.041.
   PubMed Web of Science ®Google Scholar
• Human Papillomaviruses. 90 IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, France: International Agency for Research on Cancer. 2007;689. ISBN:978-92-832-1290-4 .
   Google Scholar
• Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26(Suppl 10):K1–16. doi:10.1016/j.vaccine.2008.05.064.
   PubMed Web of Science ®Google Scholar
• Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC information centre on HPV and cancer (HPV information centre). Human papillomavirus and related diseases in Mexico. Summary Rep. 2019 Jun;17:1–171 .
   Google Scholar
• Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh P, Ferreccio C, Hieu NT, Matos E, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the international agency for research on cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366:991–98. doi:10.1016/S0140-6736(05)67069-9.
   PubMed Web of Science ®Google Scholar
• Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88:63–73. doi:10.1038/sj.bjc.6600688.
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, de Sanjosé S, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7:453–59. doi:10.1016/S1473-3099(07)70158-5.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Papenfuss M, Abrahamsen M, Denman C, de Zapien JG, Henze JL, Ortega L, Brown de Galaz EM, Stephan J, Feng J, et al. Human papillomavirus infection at the United States-Mexico border: implications for cervical cancer prevention and control. Cancer Epidemiol Biomarkers Prev. 2001;10:1129–36.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Losa Mdel R, Rosado-Lopez I, Valdez-Gonzalez N, Puerto-Solis M. High prevalence of human papillomavirus type 58 in Mexican colposcopy patients. J Clin Virol. 2004;29:202–05. doi:10.1016/S1386-6532(03)00138-0.
   PubMed Web of Science ®Google Scholar
• Jacome-Galarza I, Ito-Nakashimada MA, Figueroa-Aguilar G, Garcia-Latorre E, Salazar MI, Lopez-Orduna E, Camacho AD, Valdez-Alarcón JJ, Hernández JM, León-Avila G, et al. Prevalence of human papillomavirus in women from the state of Michoacan, Mexico, showed high frequency of unusual virus genotypes. Rev Invest Clin. 2017;69:262–69. doi:10.24875/ric.17002065.
   PubMedGoogle Scholar
• Velazquez-Marquez N, Paredes-Tello MA, Perez-Terron H, Santos-Lopez G, Reyes-Leyva J, Vallejo-Ruiz V. Prevalence of human papillomavirus genotypes in women from a rural region of Puebla, Mexico. Int J Infect Dis. 2009;13:690–95. doi:10.1016/j.ijid.2008.10.010.
   PubMed Web of Science ®Google Scholar
• Drolet M, Benard E, Perez N, Brisson M, Ali H, Boily M-C, Baldo V, Brassard P, Brotherton JML, Callander D. Group HPVVIS. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394:497–509. doi:10.1016/S0140-6736(19)30298-3.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Nygard M, Dillner J, Brooke Marshall J, Radley D, Li M, Munk C, Hansen BT, Sigurdardottir LG, Hortlund M, et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries. Clin Infect Dis. 2018;66:339–45. doi:10.1093/cid/cix797.
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, de Sanjosé S, Castellsagué X. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Global Health. 2016;4:e453–63.
   PubMed Web of Science ®Google Scholar
• World Health Organization estimates of human papillomavirus immunization coverage. 2019. [accessed 2020 Dec 14]. https://www.who.int/immunization/monitoring_surveillance/data/HPV_estimates.xls.
   Google Scholar
• Censo de población y vivienda 2020 . Mexico: Instituto Nacional de Estadística, Geografía e Informática (INEGI). [accessed 2020 Oct 22].https://www.inegi.org.mx/programas/ccpv/2020/
   Google Scholar
• Dilley S, Miller KM, Huh WK. Human papillomavirus vaccination: ongoing challenges and future directions. Gynecol Oncol. 2020;156:498–502. doi:10.1016/j.ygyno.2019.10.018.
   PubMed Web of Science ®Google Scholar
• Kotloff KL, Wasserman SS, Russ K, Shapiro S, Daniel R, Brown W, Frost A, Tabara SO, Shah K. Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sex Transm Dis. 1998;25:243–50. doi:10.1097/00007435-199805000-00005.
   PubMed Web of Science ®Google Scholar
• Revzina NV, Diclemente RJ. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. Int J STD AIDS. 2005;16:528–37. doi:10.1258/0956462054679214.
   PubMed Web of Science ®Google Scholar
• Herrera-Ortiz A, Conde-Glez CJ, Olamendi-Portugal ML, Garcia-Cisneros S, Plett-Torres T, Sanchez-Aleman MA. College women, HPV genotyping and sexual behavior before HPV vaccination: results from samples stored for a long time. J Infect Public Health. 2018;11:286–89. doi:10.1016/j.jiph.2017.08.014.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Human papillomavirus laboratory manual. Geneva: World Health Organization; 2010.
   Google Scholar
• Ramanakumar AV, Thomann P, Candeias JM, Ferreira S, Villa LL, Franco EL. Use of the normalized absorbance ratio as an internal standardization approach to minimize measurement error in enzyme-linked immunosorbent assays for diagnosis of human papillomavirus infection. J Clin Microbiol. 2010;48:791–96. doi:10.1128/JCM.00844-09.
   PubMed Web of Science ®Google Scholar
• Babicki S, Arndt D, Marcu A, Liang Y, Grant JR, Maciejewski A, Wishart DS. Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res. 2016;44:W147–53. doi:10.1093/nar/gkw419.
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–56. doi:10.1016/S1470-2045(10)70230-8.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang W, Wang Z, Wang Z, Wang Y, Wang J, Zhao, W, Li, D, Liu, H, Hao, M, . Prevalence, genotype distribution and risk factors of cervical HPV infection in Yangqu, China: a population-based survey of 10086 women. Hum Vaccines Immunother. 2019;16(7):1–8.
   PubMed Web of Science ®Google Scholar
• Pierce Campbell CM, Curado MP, Harlow SD, Soliman AS. Variation of cervical cancer incidence in Latin America and the Caribbean. Rev Panam Salud Publica. 2012;31:492–98. doi:10.1590/S1020-49892012000600007.
   PubMed Web of Science ®Google Scholar
• Dominguez Bauta SR, Trujillo Perdomo T, Aguilar Fabré K, Hernandez Menendez M. Infeccion por el virus del papiloma humano en adolescentes y adultas jovenes. Rev Cub Obst Y Ginecol. 2018;44:1–13.
   Google Scholar
• Gallegos-Bolanos J, Rivera-Dominguez JA, Presno-Bernal JM, Cervantes-Villagrana RD. High prevalence of co-infection between human papillomavirus (HPV) 51 and 52 in Mexican population. BMC Cancer. 2017;17:531. doi:10.1186/s12885-017-3519-7.
   PubMed Web of Science ®Google Scholar
• Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, Clifford, GM, Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131:2349–59. doi:10.1002/ijc.27485.
   PubMed Web of Science ®Google Scholar
• Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis. 1996;174:679–89. doi:10.1093/infdis/174.4.679.
   PubMed Web of Science ®Google Scholar
• Itarat Y, Kietpeerakool C, Jampathong N, Chumworathayi B, Kleebkaow P, Aue-Aungkul A, Nhokaew W. Sexual behavior and infection with cervical human papillomavirus types 16 and 18. Int J Womens Health. 2019;11:489–94. doi:10.2147/IJWH.S218441.
   PubMed Web of Science ®Google Scholar
• Basu P, Malvi SG, Joshi S, Bhatla N, Muwonge R, Sankaranarayanan R, Verma Y, Esmy PO, Poli URR, Shah A, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 2021;22(11):1518–29. doi:10.1016/S1470-2045(21)00453-8.
   PubMed Web of Science ®Google Scholar
• Whitworth HS, Gallagher KE, Howard N, Mounier-Jack S, Mbwanji G, Kreimer AR, Basu P, Kelly H, Drolet M, Brisson M, et al. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: a systematic review of evidence from clinical trials. Vaccine. 2020;38:1302–14. doi:10.1016/j.vaccine.2019.12.017.
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Herrero R, Sampson JN, Porras C, Lowy DR, Schiller JT, Schiffman, M, Rodriguez, AC, Chanock, S et al, . Evidence for single-dose protection by the bivalent HPV vaccine-review of the Costa Rica HPV vaccine trial and future research studies. Vaccine. 2018;36:4774–82. doi:10.1016/j.vaccine.2017.12.078.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Galaj A, Spaczynski M, Wysocki J, Kaufmann AM, Poncelet S, Suryakiran, PV, Folschweiller, N, Thomas, F, Lin, L, Struyf, F, . Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age. Cancer Med. 2017;6:2723–31. doi:10.1002/cam4.1155.
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, Nene BM, Esmy PO, Joshi S, Poli URR, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016;17:67–77. doi:10.1016/S1470-2045(15)00414-3.
   PubMed Web of Science ®Google Scholar
• Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway D. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181:1911–19. doi:10.1086/315498.
   PubMed Web of Science ®Google Scholar
• Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J, Kiviat N, Galloway DA. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis. 1996;174:927–36. doi:10.1093/infdis/174.5.927.
   PubMed Web of Science ®Google Scholar
• Beachler DC, Kreimer AR, Schiffman M, Herrero R, Wacholder S, Rodriguez AC, Lowy DR, Porras C, Schiller JT, Quint W, et al. Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection. J Natl Cancer Inst. 2016;108:djv302. doi:10.1093/jnci/djv302.
   PubMedGoogle Scholar
• Prata TT, Bonin CM, Ferreira AM, Padovani CT, Fernandes CE, Machado AP, Tozetti IA. Local immunosuppression induced by high viral load of human papillomavirus: characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions. Immunology. 2015;146:113–21. doi:10.1111/imm.12487.
   PubMed Web of Science ®Google Scholar
• Molling JW, de Gruijl TD, Glim J, Moreno M, Rozendaal L, Meijer CJ, van den Eertwegh, JM, Scheper, RJ, von Blomberg, ME, Bontkes, HJ, . CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer. 2007;121:1749–55. doi:10.1002/ijc.22894.
   PubMed Web of Science ®Google Scholar
• Enerly E, Flingtorp R, Christiansen IK, Campbell S, Hansen M, Myklebust TA, Weiderpass, E, Nygård, M, . An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway. PLoS One. 2019;14:e0223612. doi:10.1371/journal.pone.0223612.
   PubMed Web of Science ®Google Scholar
• Feiring B, Laake I, Christiansen IK, Hansen M, Stalcrantz J, Ambur OH, Magnus P, Jonassen CM, Trogstad L. Substantial decline in prevalence of vaccine-type and nonvaccine-type Human papillomavirus (HPV) in vaccinated and unvaccinated girls 5 years after implementing HPV vaccine in Norway. J Infect Dis. 2018;218:1900–10. doi:10.1093/infdis/jiy432.
   PubMed Web of Science ®Google Scholar
• Guo F, Hirth JM, Berenson AB. Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years). Hum Vaccines Immunother. 2015;11:2337–44. doi:10.1080/21645515.2015.1066948.
   PubMed Web of Science ®Google Scholar
• Lin SW, Ghosh A, Porras C, Markt SC, Rodriguez AC, Schiffman M, Wacholder S, Kemp TJ, Pinto LA, Gonzalez P, Wentzensen N. HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS One. 2013;8:e53067. doi:10.1371/journal.pone.0053067.
   PubMed Web of Science ®Google Scholar
• Mariz FC, Bender N, Anantharaman D, Basu P, Bhatla N, Pillai MR, Prabhu PR, Sankaranarayanan R, Eriksson T, Pawlita M, Prager K. Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. NPJ Vaccines. 2020;5:14. doi:10.1038/s41541-020-0165-x.
   PubMed Web of Science ®Google Scholar
• Bonanni P, Boccalini S, Bechini A. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine. 2009;27(Suppl 1):A46–53. doi:10.1016/j.vaccine.2008.10.085.
   PubMedGoogle Scholar
• Scherpenisse M, Schepp RM, Mollers M, Meijer CJ, Berbers GA, van der Klis FR, Gray C. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One. 2013;8:e74797. doi:10.1371/journal.pone.0074797.
   PubMed Web of Science ®Google Scholar